11 April 2024
Freshfields advises Haleon plc on Pfizer Inc.’s secondary global offering of Haleon shares and £315 million off-market share buyback
Capital Markets & IPO Completed
Advising firms
Deal team
9 lawyers named| Lawyer | Firm | Seniority | Practice | Office |
|---|---|---|---|---|
| Samira Afrasiabi Lead | Freshfields Bruckhaus Deringer | Partner | global transactions | Not stated |
| Tom Godwin Lead | Freshfields Bruckhaus Deringer | Partner | global transactions | Not stated |
| Julian Long Lead | Freshfields Bruckhaus Deringer | Partner | global transactions | Not stated |
| Chloe Coleman | Freshfields Bruckhaus Deringer | Associate | Not stated | Not stated |
| Toby Holborow | Freshfields Bruckhaus Deringer | Senior associate | Not stated | Not stated |
| Yoel Gordon | Freshfields Bruckhaus Deringer | Associate | Not stated | Not stated |
| May Smith | Freshfields Bruckhaus Deringer | Partner | Tax | Not stated |
| Samuel Withnall | Freshfields Bruckhaus Deringer | Senior associate | Tax | Not stated |
| Robert Jones | Freshfields Bruckhaus Deringer | Associate | Tax | Not stated |
Stated terms
- Stated value
- GBP 315m (£315 million)
- What the figure measures
- Total transaction value
- Client
- Haleon plcIssuer
- Counterparties
- Pfizer Inc. (Other)